IL209005A0 - Use of corticotropin-releasing factor for the treatment of cancer - Google Patents

Use of corticotropin-releasing factor for the treatment of cancer

Info

Publication number
IL209005A0
IL209005A0 IL209005A IL20900510A IL209005A0 IL 209005 A0 IL209005 A0 IL 209005A0 IL 209005 A IL209005 A IL 209005A IL 20900510 A IL20900510 A IL 20900510A IL 209005 A0 IL209005 A0 IL 209005A0
Authority
IL
Israel
Prior art keywords
corticotropin
cancer
treatment
releasing factor
releasing
Prior art date
Application number
IL209005A
Other languages
English (en)
Original Assignee
Neutron Row
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutron Row filed Critical Neutron Row
Publication of IL209005A0 publication Critical patent/IL209005A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL209005A 2008-04-30 2010-10-28 Use of corticotropin-releasing factor for the treatment of cancer IL209005A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4929208P 2008-04-30 2008-04-30
US9480608P 2008-09-05 2008-09-05
PCT/US2009/002645 WO2009134396A2 (en) 2008-04-30 2009-04-30 Methods of using corticotropin-releasing factor for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL209005A0 true IL209005A0 (en) 2011-01-31

Family

ID=41119761

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209005A IL209005A0 (en) 2008-04-30 2010-10-28 Use of corticotropin-releasing factor for the treatment of cancer

Country Status (17)

Country Link
US (1) US20100113341A1 (enExample)
EP (1) EP2259793A2 (enExample)
JP (1) JP2011519375A (enExample)
KR (1) KR20110021820A (enExample)
CN (1) CN102036680A (enExample)
AU (1) AU2009241813A1 (enExample)
CA (1) CA2722426A1 (enExample)
CO (1) CO6300959A2 (enExample)
CR (1) CR11762A (enExample)
EC (1) ECSP10010631A (enExample)
IL (1) IL209005A0 (enExample)
MX (1) MX2010011882A (enExample)
NI (1) NI201000185A (enExample)
NZ (1) NZ588877A (enExample)
RU (1) RU2010148803A (enExample)
WO (1) WO2009134396A2 (enExample)
ZA (1) ZA201007729B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057962A2 (en) * 2008-11-19 2010-05-27 Neutron Limited Crf conjugates with extended half-lives
KR20120124353A (ko) * 2009-06-24 2012-11-13 스티븐 에반스-프레케 암 치료를 위해 코르티코트로핀 방출인자를 사용하는 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852054A (en) * 1956-11-23 1958-09-16 Motley Murat Brunson Container and closure therefor
US4312523A (en) * 1979-10-29 1982-01-26 Paco Packaging Incorporated Label for container having pharmaceutical product therein
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
WO1984001378A1 (en) 1982-09-29 1984-04-12 Karl P Lederis Urotensin peptides
US4528189A (en) * 1983-02-03 1985-07-09 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5229940A (en) * 1992-01-29 1993-07-20 Conoco Inc. Method of extracting three dimensional information from a grid of two dimensional seismic data
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6319900B1 (en) * 1999-09-21 2001-11-20 The Regents Of The University Of California Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
CN1361180A (zh) * 2000-12-26 2002-07-31 上海博德基因开发有限公司 一种新的多肽——促肾上腺皮质激素释放因子8.8和编码这种多肽的多核苷酸
CN1382700A (zh) * 2001-04-26 2002-12-04 上海博德基因开发有限公司 一种多肽——促肾上腺皮质激素释放因子－12.87和编码这种多肽的多核苷酸
CA2358177A1 (en) * 2001-10-03 2003-04-03 Ted Ramsay Label for pharmaceutical prescriptions
US7919118B2 (en) * 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
KR101235723B1 (ko) * 2004-07-08 2013-02-21 아임스코 리미티드 약제
JP2006036013A (ja) * 2004-07-27 2006-02-09 Yamaha Motor Co Ltd 自動二輪車
US7311205B2 (en) * 2005-01-25 2007-12-25 Target Brands, Inc. Pharmacy bottle system including label
US20100203048A1 (en) * 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer

Also Published As

Publication number Publication date
US20100113341A1 (en) 2010-05-06
CA2722426A1 (en) 2009-11-05
AU2009241813A1 (en) 2009-11-05
CR11762A (es) 2011-04-26
RU2010148803A (ru) 2012-06-10
ECSP10010631A (es) 2011-02-28
WO2009134396A2 (en) 2009-11-05
EP2259793A2 (en) 2010-12-15
JP2011519375A (ja) 2011-07-07
NZ588877A (en) 2012-08-31
NI201000185A (es) 2013-04-22
CO6300959A2 (es) 2011-07-21
WO2009134396A3 (en) 2010-04-15
CN102036680A (zh) 2011-04-27
KR20110021820A (ko) 2011-03-04
MX2010011882A (es) 2011-02-25
ZA201007729B (en) 2014-02-26

Similar Documents

Publication Publication Date Title
PL2303021T3 (pl) Związki do leczenia nowotworu
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
PT2340042E (pt) Métodos e composições para o tratamento de cancro
ZA201105986B (en) Substituted pyrimidines for the treatment of cancer
IL211193A0 (en) Bicyclic triazole derivatives for the treatment of tumours
ZA201005248B (en) 4-pyridinone compounds and their use for cancer
IL215772A0 (en) Composition for the treatment of prostate cancer
SG173672A1 (en) Novel ortho-aminoamides for the treatment of cancer
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
GB0804496D0 (en) Treating cancer
PT3330383T (pt) Grn163l para utiliização como inibidor de telomerase no tratamento de cancro
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
IL206189A0 (en) Compound for use in the treatment of cancer
ZA201109508B (en) Methods of using corticotropin-releasing factor for the treatment of cancer
ZA201007729B (en) Use of corticotropin-releasing factor for the treatment of cancer
GB0809046D0 (en) Cancer treatment
IL205339A0 (en) Compounds and methods for the treatment of cancer
HK1149475A (en) Use of corticotropin-releasing factor for the treatment of cancer
HK1159496A (en) Methods of using corticotropin-releasing factor for the treatment of cancer
GB0809319D0 (en) The treatment of puritus
GB0712513D0 (en) Treatment of cancer
HK1162949A (zh) 治療癌症的組合療法